Physician profile
William D Posten
NPI 1497725790
$2,720.97
in general payments reported to CMS, 2019-2025
25 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $48.62 · 2021: $73.33 · 2022: $184 · 2023: $356 · 2024: $781 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $674.69 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Amgen INC. | $257.40 | 2022-2024 | Otezla |
| Abbvie INC. | $254.56 | 2019-2025 | |
| Keswick Pharmaceuticals LLC | $249.07 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.77 | 2019-2023 | Jublia, Duobrii, Arazlo |
| Regeneron Healthcare Solutions, INC. | $160.16 | 2019-2025 | Libtayo |
| Janssen Biotech, INC. | $130.01 | 2024 | Tremfya |
| Convatec INC. | $121.30 | 2023-2025 | |
| Genzyme Corporation | $104.15 | 2023 | |
| Sensus Healthcare, INC. | $80.10 | 2024 | |
| Biotissue Holdings INC. | $65.39 | 2023 | |
| Galderma Laboratories, L.P. | $64.49 | 2019 | |
| Organogenesis INC. | $54.45 | 2021-2023 | Puraply |
| Allergan, INC. | $47.71 | 2019 | |
| Biowound Solutions, INC. | $37.85 | 2025 | Bio-Connekt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $34.91 | 2025 | |
| Sun Pharmaceutical Industries INC. | $33.20 | 2022 | |
| Melinta Therapeutics, LLC | $31.86 | 2019 | |
| Smith+Nephew, INC. | $31.09 | 2019 | |
| Next Science LLC | $27.15 | 2020 | |
| Merck Sharp & Dohme LLC | $26.01 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.62 | 2021 | |
| Genentech USA, INC. | $18.47 | 2019 | |
| Medtronic, INC. | $14.56 | 2025 | Midas Rex |
| Biofrontera INC. | $7.00 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Posten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.